ClinicalTrials.gg
TerminatedNCT06466187Updated Jul 7, 2026

A Study of SGN-MesoC2 in Advanced Solid Tumors

A Phase 1 interventional study of PF-08052666 in Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms and Pancreatic Adenocarcinoma, sponsored by Seagen, a wholly owned subsidiary of Pfizer. Terminated at 19 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Seagen, a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 1, Interventional, and Treatment

Why this study was terminated
The trial was terminated for strategic reasons. The decision was not based on any safety concerns

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer — 15 open to participants now, 26 under way, 5 of them phase 3. Carcinoma, Non-Small-Cell Lung · Pfizer.

Enrollment
115th of 136
19 · median 79
Started
2024
with 10 others
Phase 1
56 of 158
6 open now
Registered
141st of 158
by date

Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, this one is the 115th largest by enrollment of the 136 interventional ones that give a count, is one of 11 that started in 2024, is one of 56 in phase 1, and was the 141st registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

15 of the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, or all of them as a file.
02

Study summary

This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat.

Patients in this study must have cancer that has come back or did not get better with treatment. Patients must have a solid tumor cancer that can't be treated with standard of care drugs.

This clinical trial uses an experimental drug called PF-08052666/SGN-MesoC2. PF-08052666/SGN-MesoC2 is a type of antibody-drug conjugate (ADC). ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells.

This study will have 3 parts. Part A and Part B of the study will find out how much PF-08052666/SGN-MesoC2 should be given to participants. Part C will use the information from Parts A and B to see if PF-08052666/SGN-MesoC2 is safe and if it works to treat solid tumor cancers.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
  • Ovarian Neoplasms
  • Pancreatic Adenocarcinoma
  • Colorectal Neoplasms
  • Mesothelioma
  • Other Solid Tumors
  • Endometrial

Keywords

  • NSCL
  • Lung Neoplasm
  • Cancer of Ovary
  • Ovarian Cancer
  • Colorectal Cancer
  • Colorectal Tumors
  • Endometrial
  • Seattle Genetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or older.
  • - or cytologically-confirmed or locally advanced unresectable platinum-resistant ovarian cancer, NSCLC, pancreatic ductal adenocarcinoma, endometrial cancer, colorectal cancer, or mesothelioma, who have or progressed following standard therapies, or for which no standard therapies are available.
  • An performance status score of 0 or 1.
  • At least 1 at baseline based on Version 1.1 (RECIST v1.1).
  • or a fresh tumor biopsy during the screening period.
  • Adequate hepatic, renal and bone marrow function.
  • Participants must not have received more than 2 lines of cytotoxic systemic therapy in the metastatic setting (Parts B and C only).

Exclusion criteria

Exclusion Criteria:

  • Previously received or currently receiving any systemic anticancer therapy or focal radiotherapy within 4 weeks prior to the first dose of MesoC2 or within 2 weeks prior to the first dose of MesoC2 if the underlying disease had progressed on treatment.
  • Prior anti-MSLN antibody or MSLN-directed ADC (Part C only).
  • Unresolved toxicities from prior therapy greater than v5.0 grade 1 at the time of study treatment (except alopecia).
  • Inadequate hepatic dysfunction, renal function, or hematologic abnormalities.
  • Previously untreated . Participants who received radiation or surgery for brain metastases are eligible if therapy was completed at least 4 weeks prior to study treatment initiation, and there was no evidence of central nervous system progression nor requirements for chronic therapy
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    PF-08052666

    PF-08052666 monotherapy

    Drug: PF-08052666

Interventions

  • DrugPF-08052666

    Given into the vein (IV; intravenously)

    Also known as: HBM9033; SGN-MesoC2

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Through 30-37 days after the last dose of study treatment, 48 Months

  2. Number of participants with laboratory abnormalities

    Time frame: Through 30-37 days after the last dose of study treatment, 48 Months

  3. Number of participants with dose modifications

    Frequency of dose modifications (eg, dose delay, treatment interruptions, dose reductions and treatment discontinuations) due to AEs

    Time frame: Up to 4 months

  4. Number of participants with dose-limiting toxicities (DLTs)

    Incidence of dose-limiting toxicities (DLTs)

    Time frame: Cycle 1 (21 days)

Secondary outcomes

  1. Objective response rate (ORR)

    ORR is defined as the proportion of participants in the relevant analysis set with best response of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

    Time frame: Approximately 1 year 4 months

  2. Best response

    The best timepoint response achieved for the subject during the protocol specified period according to RECIST V1.1.

    Time frame: Approximately 1 year 4 months

  3. Duration of response (DOR)

    DOR is defined as the time interval from first occurrence of documented objective response to the time of progressive disease (PD) according to RECIST v1.1 or death from any cause, whichever comes first.

    Time frame: Approximately 1 year 4 months

  4. Disease control rate (DCR)

    DCR is defined as the proportion of participants with best response of CR, PR or stable disease (SD) according to RECIST v1.1.

    Time frame: Approximately 1 year 4 months

  5. Progression-free survival (PFS)

    PFS is defined as the time from first dosing to the first occurrence of PD according to RECIST v1.1 or death from any cause, whichever comes first.

    Time frame: Approximately 1 year 4 months

  6. Overall survival (OS)

    Overall survival (OS) defined as the time from first dosing to death.

    Time frame: Approximately 1 year 4 months

  7. Pharmacokinetic (PK) parameter - Area under the serum concentration (AUC)

    Time frame: Cycles 1, 2, and 3 (each cycle is up to 21 days)

  8. Pharmacokinetic (PK) parameter - Maximum serum concentration (Cmax)

    Time frame: Cycles 1, 2, and 3 (each cycle is up to 21 days)

  9. Pharmacokinetic (PK) parameter - Time to reach maximum serum concentration (Tmax)

    Time frame: Cycles 1, 2, and 3 (each cycle is up to 21 days)

  10. Pharmacokinetic (PK) parameter - Half-life

    Time frame: Cycles 1, 2, and 3 (each cycle is up to 21 days)

  11. Number of participants with antidrug antibodies

    Time frame: Cycles 1, 2, and 3 (each cycle is up to 21 days)

07

Study locations

19 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • The University of Alabama at Birmingham
    Birmingham, Alabama 35249, United States
  • University of Alabama at Birmingham
    Birmingham, Alabama 35249, United States
  • The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • The University of Kansas Clinical Research Center
    Fairway, Kansas 66205, United States
  • The University of Kansas Hospital Cambridge North Tower A
    Kansas City, Kansas 66160, United States
  • The University of Kansas Hospital
    Kansas City, Kansas 66160, United States
  • The University of Kansas Medical Center Medical Office Building
    Kansas City, Kansas 66160, United States
  • The University of Kansas Cancer Center - Indian Creek Campus
    Overland Park, Kansas 66211, United States
  • The University of Kansas Cancer Center - Westwood
    Westwood, Kansas 66205, United States
  • The University of Kansas Cancer Center, Investigational Drug Services
    Westwood, Kansas 66205, United States
  • Atrium Health Wake Forest Baptist
    Winston-Salem, North Carolina 27157, United States
  • Sarah Cannon Research Institute - Pharmacy
    Nashville, Tennessee 37203, United States
  • SCRI Oncology Partners
    Nashville, Tennessee 37203, United States
  • START San Antonio, LLC
    San Antonio, Texas 78229, United States
  • START Mountain Region, LLC
    West Valley City, Utah 84119, United States
  • University Health Network
    Toronto, Ontario M5G 2C4, Canada
  • University Health Network, Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
  • McGill University Health Centre
    Montreal, Quebec H4A 3J1, Canada
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in May 2026, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2024
First posted
Jun 20, 2024
StartActual
Aug 2, 2024
Primary completionActual
May 27, 2026
CompletionActual
May 27, 2026
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06466187
Responsible party
Sponsor
First posted
Jun 20, 2024
Start date
Aug 2, 2024
Primary completion
May 27, 2026
Completion
May 27, 2026
Last update
Jul 7, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion